Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.In this episode of Skinfluenced: The Skin Podcast, we take a break from only skin diseases, and delve into our wellness side to take a look into some ground breaking research shaping the understanding and treatment of the newest GLP-1 indication: metabolic dysfunction–associated steatohepatitis (MASH). Join us as we dive into the groundbreaking developments surrounding semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and its expanding therapeutic potential from upcoming FDA approvals to emerging pharmacologic strategies, this episode breaks down what these findings mean for providers, patients, and the future of disease management.#Semaglutide #MASH #LiverDisease #GLP1agonist #Wegovy #LiverFibrosis #Steatohepatitis #MetabolicHealth #Obesity #Type2Diabetes #WeightLoss #Cardiometabolic #ClinicalTrials #FDAApproval #ESSENCEtrial #HeartFailure #HFpEF #ChronicKidneyDisease #NeurodegenerativeDiseases #AlzheimersDisease #ParkinsonsDisease #MASLD #NAFLD #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast Link to Source(s):FDA (2024): FDA Approves Treatment for Serious Liver Disease Known as MASHhttps://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mashJournal of Hepatology (2020): A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statementhttps://www.sciencedirect.com/science/article/abs/pii/S0168827820302014PubMed (2022): Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative Diseases: A Narrative Reviewhttps://pubmed.ncbi.nlm.nih.gov/35650449/PubMed (2023): Efficacy and Safety of Semaglutide in Non-Alcoholic Fatty Liver Diseasehttps://pubmed.ncbi.nlm.nih.gov/37899788/PubMed (2024): Semaglutide Versus Placebo in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Pooled Analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Randomised Trialshttps://pubmed.ncbi.nlm.nih.gov/39222642/PubMed (2025): Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitishttps://pubmed.ncbi.nlm.nih.gov/40004240/The New England Journal of Medicine (2023): Semaglutide and Cardiovascular Outcomes in Obesity without Diabeteshttps://www.nejm.org/doi/full/10.1056/NEJMoa2307563The New England Journal of Medicine (2025): Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitishttps://scholarindexing.com/uploads/files/8pu3_1ome6lcxkb.pdf

Ver todos los episodios